Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers

NCT02831231 is registered in ClinicalTrials.gov with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor.

NCT NCT02831231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02831231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase
Phase 1
Overall status
Completed
Start date
September 7, 2016
Completion date
October 28, 2016
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia